{"id":16582,"date":"2026-02-17T19:35:34","date_gmt":"2026-02-17T19:35:34","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/16582\/"},"modified":"2026-02-17T19:35:34","modified_gmt":"2026-02-17T19:35:34","slug":"novo-nordisk-faces-wegovy-dose-expansion-and-new-generic-competition","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/16582\/","title":{"rendered":"Novo Nordisk Faces Wegovy Dose Expansion And New Generic Competition"},"content":{"rendered":"\n

Track your investments for FREE<\/a> with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.<\/p>\n

European Commission approves a higher 7.2 mg maintenance dose of Wegovy for obesity treatment across the EU.<\/p>\n

Dr Reddy’s Laboratories prepares to launch a lower cost generic version of Wegovy in India.<\/p>\n

These developments arrive as Novo Nordisk, ticker CPSE:NOVO B, trades at DKK308.45 with mixed multi year share returns.<\/p>\n

Novo Nordisk, CPSE:NOVO B, is tightening its focus on obesity care with an EU wide green light for a higher 7.2 mg Wegovy dose. This could be relevant for patients and clinicians looking for more dosing flexibility. The stock currently trades at DKK308.45, with a 5 year return of 53.8%, a 1 year return showing a 46.0% decline, and a 30 day return showing a 20.7% decline. This frames the news against a period of share price pressure.<\/p>\n

At the same time, Dr Reddy’s push to introduce a generic Wegovy competitor in India highlights how pricing and access pressures are building around obesity drugs globally. For investors, these twin updates point to both potential volume expansion for Wegovy in Europe and rising competition in price sensitive markets. This creates a more complex backdrop for assessing Novo Nordisk’s obesity franchise over the medium term.<\/p>\n

Stay updated on the most important news stories for Novo Nordisk<\/a> by adding it to your watchlist<\/a> or portfolio<\/a>. Alternatively, explore our Community<\/a> to discover new perspectives on Novo Nordisk.<\/p>\n

\"CPSE:NOVO<\/a> CPSE:NOVO B Earnings & Revenue Growth as at Feb 2026 <\/p>\n

4 things going right for Novo Nordisk that this headline doesn’t cover.<\/a><\/p>\n

\u2705 Price vs Analyst Target: At DKK308.45 versus a consensus target of DKK379.36, the price sits about 19% below analyst expectations.<\/p>\n

\u2705 Simply Wall St Valuation: Shares are flagged as trading 65.7% below estimated fair value, with an \u201cundervalued\u201d status.<\/p>\n

\u274c Recent Momentum: The stock has seen a 20.7% decline over the past 30 days.<\/p>\n

To assess whether it may be the right time to buy, sell or hold Novo Nordisk, you can review Simply Wall St’s company report for the latest analysis of Novo Nordisk’s fair value.<\/p>\n

\ud83d\udcca The higher 7.2 mg Wegovy dose in the EU could influence future obesity drug volumes and pricing power in Novo Nordisk’s core market.<\/p>\n

\ud83d\udcca It may be useful to monitor how revenue, margins and P\/E change as the company balances premium dosing in Europe with pricing pressure from a generic rival in India.<\/p>\n

\u26a0\ufe0f The flagged high level of debt and use of non cash earnings may become more important if competition affects cash generation from obesity products.<\/p>\n

For a broader view, including more information on risks and potential rewards, you can read the complete Novo Nordisk analysis. You can also visit the community page for Novo Nordisk to see how other investors believe this latest news may influence the company’s narrative.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include NOVO-B.CO<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…\n","protected":false},"author":2,"featured_media":759,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[11998,2610,11888,272],"class_list":["post-16582","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-dr-reddy","tag-european-commission","tag-maintenance-dose","tag-novo-nordisk"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/16582","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=16582"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/16582\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/759"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=16582"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=16582"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=16582"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}